218 related articles for article (PubMed ID: 22503047)
21. Testing for urinary hyaluronate improves detection and grading of transitional cell carcinoma.
Passerotti CC; Srougi M; Bomfim AC; Martins JR; Leite KR; Dos Reis ST; Sampaio LO; Ortiz V; Dietrich CP; Nader HB
Urol Oncol; 2011; 29(6):710-5. PubMed ID: 19962919
[TBL] [Abstract][Full Text] [Related]
22. Real time reverse transcriptase polymerase chain reaction of urinary cytokeratin 20 detects transitional cell carcinoma cells.
Inoue T; Nakanishi H; Inada K; Hioki T; Tatematsu M; Sugimura Y
J Urol; 2001 Dec; 166(6):2134-41. PubMed ID: 11696722
[TBL] [Abstract][Full Text] [Related]
23. Evaluation of urinary level of NMP22 as a diagnostic marker for stage pTa-pT1 bladder cancer: comparison with urinary cytology and BTA test.
Del Nero A; Esposito N; Currò A; Biasoni D; Montanari E; Mangiarotti B; Trinchieri A; Zanetti G; Serrago MP; Pisani E
Eur Urol; 1999 Feb; 35(2):93-7. PubMed ID: 9933801
[TBL] [Abstract][Full Text] [Related]
24. Prognostic significance of matrix metalloproteinase-1 and tissue inhibitor of metalloproteinase-1 in voided urine samples from patients with transitional cell carcinoma of the bladder.
Durkan GC; Nutt JE; Rajjayabun PH; Neal DE; Lunec J; Mellon JK
Clin Cancer Res; 2001 Nov; 7(11):3450-6. PubMed ID: 11705862
[TBL] [Abstract][Full Text] [Related]
25. Urinary and tissue levels of scatter factor in transitional cell carcinoma of bladder.
Rosen EM; Joseph A; Jin L; Yao Y; Chau MH; Fuchs A; Gomella L; Hastings H; Goldberg ID; Weiss GH
J Urol; 1997 Jan; 157(1):72-8. PubMed ID: 8976219
[TBL] [Abstract][Full Text] [Related]
26. Use of a new tumor marker, urinary NMP22, in the detection of occult or rapidly recurring transitional cell carcinoma of the urinary tract following surgical treatment.
Soloway MS; Briggman V; Carpinito GA; Chodak GW; Church PA; Lamm DL; Lange P; Messing E; Pasciak RM; Reservitz GB; Rukstalis DB; Sarosdy MF; Stadler WM; Thiel RP; Hayden CL
J Urol; 1996 Aug; 156(2 Pt 1):363-7. PubMed ID: 8683680
[TBL] [Abstract][Full Text] [Related]
27. [Urinary BTA-TRAK in the follow-up of superficial transitional-cell bladder carcinoma].
Fernández Gómez JM; García Rodríguez J; Escaf Barmadah S; Raigoso P; Rodríguez Martínez JJ; Allende MT; Casasola Chamorro J; Rodríguez Faba O; Martín Benito JL; Regadera Sejas FJ
Arch Esp Urol; 2002; 55(1):41-9. PubMed ID: 11957750
[TBL] [Abstract][Full Text] [Related]
28. Multi-institutional external validation of urinary TWIST1 and NID2 methylation as a diagnostic test for bladder cancer.
Fantony JJ; Abern MR; Gopalakrishna A; Owusu R; Jack Tay K; Lance RS; Inman BA
Urol Oncol; 2015 Sep; 33(9):387.e1-6. PubMed ID: 26027762
[TBL] [Abstract][Full Text] [Related]
29. Appraisal of diagnostic ability of UCA1 as a biomarker of carcinoma of the urinary bladder.
Srivastava AK; Singh PK; Rath SK; Dalela D; Goel MM; Bhatt ML
Tumour Biol; 2014 Nov; 35(11):11435-42. PubMed ID: 25123267
[TBL] [Abstract][Full Text] [Related]
30. Expression of estrogen receptors-alpha and -beta in bladder cancer cell lines and human bladder tumor tissue.
Shen SS; Smith CL; Hsieh JT; Yu J; Kim IY; Jian W; Sonpavde G; Ayala GE; Younes M; Lerner SP
Cancer; 2006 Jun; 106(12):2610-6. PubMed ID: 16700038
[TBL] [Abstract][Full Text] [Related]
31. Expression of cytokeratin 20 in urinary cytology of patients with bladder carcinoma.
Klein A; Zemer R; Buchumensky V; Klaper R; Nissenkorn I
Cancer; 1998 Jan; 82(2):349-54. PubMed ID: 9445193
[TBL] [Abstract][Full Text] [Related]
32. Expression analysis of VEGF-A and VEGF-B: relationship with clinicopathological parameters in bladder cancer.
Fauconnet S; Bernardini S; Lascombe I; Boiteux G; Clairotte A; Monnien F; Chabannes E; Bittard H
Oncol Rep; 2009 Jun; 21(6):1495-504. PubMed ID: 19424629
[TBL] [Abstract][Full Text] [Related]
33. Evaluation of NMP22 in the detection of transitional cell carcinoma of the bladder.
Stampfer DS; Carpinito GA; Rodriguez-Villanueva J; Willsey LW; Dinney CP; Grossman HB; Fritsche HA; McDougal WS
J Urol; 1998 Feb; 159(2):394-8. PubMed ID: 9649246
[TBL] [Abstract][Full Text] [Related]
34. Identification of a three-gene expression signature of early recurrence in non-muscle-invasive urothelial cell carcinoma of the bladder.
Dubosq F; Ploussard G; Soliman H; Turpin E; Latil A; Desgrandchamps F; de The H; Mongiat-Artus P
Urol Oncol; 2012; 30(6):833-40. PubMed ID: 21489836
[TBL] [Abstract][Full Text] [Related]
35. [Expression of the tumormarker p16INK4a in cytology specimens of the urinary bladder. A new means for early recognition and surveillance of urothelial cancer].
Tauber S; Brunken C; Vierbuchen M
Urologe A; 2011 Sep; 50(9):1130-3. PubMed ID: 21847682
[TBL] [Abstract][Full Text] [Related]
36. Urinary cytokeratin 20 mRNA expression has the potential to predict recurrence in superficial transitional cell carcinoma of the bladder.
Christoph F; Weikert S; Wolff I; Schostak M; Tabiti K; Müller M; Miller K; Schrader M
Cancer Lett; 2007 Jan; 245(1-2):121-6. PubMed ID: 16473461
[TBL] [Abstract][Full Text] [Related]
37. Urinary NID2 and TWIST1 methylation to augment conventional urine cytology for the detection of bladder cancer.
Fantony JJ; Longo TA; Gopalakrishna A; Owusu R; Lance RS; Foo WC; Inman BA; Abern MR
Cancer Biomark; 2017; 18(4):381-387. PubMed ID: 28106542
[TBL] [Abstract][Full Text] [Related]
38. Urinary hyaluronic acid and hyaluronidase: markers for bladder cancer detection and evaluation of grade.
Lokeshwar VB; Obek C; Pham HT; Wei D; Young MJ; Duncan RC; Soloway MS; Block NL
J Urol; 2000 Jan; 163(1):348-56. PubMed ID: 10604388
[TBL] [Abstract][Full Text] [Related]
39. Increased expression of EZH2, a polycomb group protein, in bladder carcinoma.
Arisan S; Buyuktuncer ED; Palavan-Unsal N; Caşkurlu T; Cakir OO; Ergenekon E
Urol Int; 2005; 75(3):252-7. PubMed ID: 16215315
[TBL] [Abstract][Full Text] [Related]
40. Urinary cytokeratin 20 as a marker for transitional cell carcinoma.
Rotem D; Cassel A; Lindenfeld N; Mecz Y; Sova Y; Resnick M; Stein A
Eur Urol; 2000 May; 37(5):601-4. PubMed ID: 10765100
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
